2024 AACR LBx Poster: Determination of tumor PSMA expression and response to Lutetium-PSMA in men with prostate cancer using a novel epigenomic liquid biopsy platform
2024 AACR LBx Poster: Determination of tumor PSMA expression and response to Lutetium-PSMA in men with prostate cancer using a novel epigenomic liquid biopsy platform
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
2024 ECTRIMS Poster: A novel comprehensive epigenomic liquid biopsy assay reveals disease biology in multiple sclerosis patients from 1 mL of plasma
2024 ECTRIMS Poster: A novel comprehensive epigenomic liquid biopsy assay reveals disease biology in multiple sclerosis patients from 1 mL of plasma
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
2024 ESMO Poster: Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform
2024 ESMO Poster: Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging
Cell Reports “Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma”
Cell Reports “Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma”
Clinical Cancer Research “Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling”
Clinical Cancer Research “Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling”
2024 ASCO Poster: Novel epigenomic liquid biopsy assay to predict estrogen receptor (ER) status and to infer ER pathway activation in breast cancer
2024 ASCO Poster: Novel epigenomic liquid biopsy assay to predict estrogen receptor (ER) status and to infer ER pathway activation in breast cancer
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test